Effect of Out of Plane and In Plane Injection Techniques in Patients With Carpal Tunnel Syndrome

NCT05343351 | Completed

• 1 other identifier: 25.03.2022/109
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of this study, using two different injection techniques,

1. 1.To evaluate the patients in terms of the pain they feel during the application of carpal tunnel syndrome (CTS) injection,
2. 2.Evaluation in terms of undesirable effects developing after injection,
3. 3.To evaluate the degree of pain/drowsiness, symptom severity and functionality, and median nerve diameter at the end of the first month after the injection, and to evaluate the relationship of these parameters with the pain felt by the patients during the injection.

Conditions

Carpal Tunnel Syndrome; Pain; Carpal Tunnel

Outcome Measures

Primary Outcomes (6)

• Assessment of pain during injection

  Patients will be asked to rate the average level of pain they feel during the injection as absent, mild, moderate, severe, and unbearable.

  1 hour

• Pain/Numbness Evaluation

  The severity of pain and numbness of the patients will be questioned by visual analog scale (VAS). A horizontal straight line 10 cm long will be used in the VAS assessment. The patient will be told that a value of 0 represents no pain and numbness, and a value of 10 represents the most severe pain and numbness he has ever felt. In each evaluation, the average of the day and night pain/numbness severity over the last 3 days will be questioned.

  3 days

• Evaluation of symptom severity and functionality

  The Boston Carpal Tunnel Syndrome Questionnaire (BCTQ) with Turkish validity and reliability will be used to evaluate the symptom severity and functionality of the patients. BCTQ is a self-filled questionnaire consisting of two parts: symptom severity scale (SSS) and functional status scale (FSS). Each item in both sections has five different answers that score between 1 and 5. The mean score is obtained by dividing the total score by the number of questions and ranges from 1 to 5, with a higher score indicating severe symptom. Average scores are calculated separately for symptom severity and functional status.

  3 days

• Evaluation of undesirable effects

  At the controls at the end of the 4th week after the injection, the patients had skin discoloration or fat atrophy, steroid exacerbation (transient pain that started at the 24th hour after the injection and lasted an average of 2-5 days after the injection), superficial infection and median nerve irritation (from the injection). Finger numbness or weakness lasting more than 2 weeks after injection, increasing compared to pre-injection) will be evaluated.

  1 day

• Sonographic evaluation of the median nerve

  Ultrasonographic evaluation will be performed with an 18-6 MHz superficial linear probe (Esaote MyLab Five LA435 Transducer). Fixed frequency and depth settings will be used for all measurements. During the examination, patients will be performed in a sitting position facing the clinician, with the elbow in 90° flexion, the forearm supinated, and the fingers in the semi-flexion position. The examination will begin by seeing the median nerve in the axial plane at the wrist localization, and the cross-sectional area of the median nerve (MSCA) will be measured with the probe at the level of the psiform and scaphoid bone. In the measurements, the hyperechoic sheath will be excluded from the drawing and the manual trace method available in the USG device will be used. Square millimeter (mm2) unit will be used for area values in all measurements. All measurements will be made in triplicate and the average of the three measurements will be taken.

  1 day

• Descriptive information

  Age, gender, education level, body mass index, duration of symptoms, dominant hand, injection hand, and CTS severity detected in EMG of the patients included in the study will be recorded.

  1 day

Study Arms (2)

Out of Plane arm

EXPERIMENTAL

The patient group who was injected using the ultrasound-guided out of plane injection method.

Other: Technique of injection method

In Plane arm

EXPERIMENTAL

The group of patients who were injected using the ultrasound-guided in-plane injection method.

Other: Technique of injection method

Interventions

Technique of injection method OTHER

In 'out of plane group', the ultrasound probe will be placed at the entrance level of the proximal carpal tunnel (scaphoid-pisiform plane), the ulnar edge of the median nerve will be taken to the midpoint of the probe, and then the needle will be inserted from the middle point of the probe with the out of plane method. Then the needle will be advanced towards the ulnar side of the median nerve and the injection content will be given into the tunnel. In 'in plane group group', the ultrasound probe will be placed at the proximal carpal tunnel entrance level (scaphoid-pisiform plane), it will be entered at a cross angle between the ulnar artery and the median nerve with the in-plane method, and be advanced under the median nerve, and then the injection content will be given into the carpal tunnel.

In Plane arm; Out of Plane arm

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥18
• Numbness and tingling in the median nerve innervation area with or without pain
• Worsening of symptoms at night
• Positive Tinel and/or Phalen sign
• Symptom duration longer than 12 weeks
• Electrophysiologically mild or moderate CTS being diagnosed.

You may not qualify if:

• Presence of conditions such as cervical radiculopathy, polyneuropathy, brachial plexopathy, thoracic outlet syndrome that may mimic CTS
• Presence of multiple entrapment neuropathy
• Weakness in hand thumb abduction or opposition
• Thenar atrophy
• Presence of wrist corticosteroid and/or local anesthetic injection
• Regular use of medical treatment such as oral corticosteroids or NSAIDs
• Having entered a physical therapy program due to CTS in the last 6 months before the injection
• A history of trauma or arthritis attack at the wrist level
• Previous surgery due to CTS
• Thyroid diseases, diabetes, chronic kidney failure
• Having bifid median nerve, persistent median artery, ganglion cyst, tenosynovitis or tendinitis on wrist USG
• Rheumatological disease (rheumatoid arthritis, ankylosing spondylitis, systemic lupus) erythematosus, vasculitis, systemic sclerosis, dermatomyositis)
• Presence of malignancy
• Pregnant or breastfeeding mothers
• Infection or skin lesion at the injection site

Sponsors & Collaborators

• Istanbul University - Cerrahpasa: lead
• Istanbul Training and Research Hospital: collaborator

Study Sites (1)

Istanbul Training and Research Hospital

Istanbul, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Carpal Tunnel Syndrome; Pain; Median Neuropathy

Condition Hierarchy (Ancestors)

Mononeuropathies; Peripheral Nervous System Diseases; Neuromuscular Diseases; Nervous System Diseases; Nerve Compression Syndromes; Cumulative Trauma Disorders; Sprains and Strains; Wounds and Injuries; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Medical Doctor

Study Record Dates

• First Submitted: April 18, 2022
• First Posted: April 25, 2022
• Study Start: April 1, 2022
• Primary Completion: December 1, 2022
• Study Completion: February 21, 2023
• Last Updated: February 28, 2023

Record last verified: 2023-02

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)